Tango Therapeutics (TNGX) Common Equity (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Common Equity of $391.5 million for Q1 2026, up 134.78% year-over-year from $166.8 million in Q1 2025, and up 13.09% quarter-over-quarter from $346.2 million in Q4 2025.
Tango Therapeutics (TNGX) Common Equity (2020 - 2026) Analysis & Trends
Tango Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $391.5 million for Q1 2026.
- In Q1 2026, Common Equity rose 134.78% year-over-year to $391.5 million; the TTM figure through Mar 2026 stood at $391.5 million (up 134.78% YoY), while the FY2025 annual figure was $346.2 million, up 73.51% from the prior year.
- Common Equity for Q1 2026 stood at $391.5 million, up from $346.2 million in the prior quarter.
- The five-year high for Common Equity was $391.5 million in Q1 2026, with the low at $135.0 million in Q2 2025.
- The 5-year median for Common Equity is $249.5 million (2022), against an average of $250.1 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity jumped 453.38% in 2022, then plunged 45.51% in 2025.
- Tango Therapeutics' Common Equity stood at $249.5 million in 2022, then grew by 1.46% to $253.1 million in 2023, then fell by 21.17% to $199.5 million in 2024, then jumped by 73.51% to $346.2 million in 2025, then climbed by 13.09% to $391.5 million in 2026.
- Business Quant data shows TNGX's Common Equity at $391.5 million in Q1 2026, $346.2 million in Q4 2025, and $160.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 1.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Bn |
| Mar 31, 2026 | 391.51 Mn |
| Dec 31, 2025 | 346.18 Mn |
| Sep 30, 2025 | 160.03 Mn |
| Jun 30, 2025 | 134.95 Mn |
| Mar 31, 2025 | 166.76 Mn |
| Dec 31, 2024 | 199.52 Mn |
| Sep 30, 2024 | 229.17 Mn |
| Jun 30, 2024 | 247.67 Mn |
| Mar 31, 2024 | 264.45 Mn |
| Dec 31, 2023 | 253.11 Mn |
| Sep 30, 2023 | 276.60 Mn |
| Jun 30, 2023 | 212.95 Mn |
| Mar 31, 2023 | 227.26 Mn |
| Dec 31, 2022 | 249.48 Mn |
| Sep 30, 2022 | 273.07 Mn |
| Jun 30, 2022 | 298.70 Mn |
| Mar 31, 2022 | 320.36 Mn |
| Dec 31, 2021 | 344.75 Mn |
| Sep 30, 2021 | 365.41 Mn |